Evaluation of L/N type Ca2+ channel blocker (cilnidipine) in hypertension complicated diabetes or sleep apnea syndrome ; Trial for the effects of improvementof arteriosclerosis and renal function

Autores [No se listan los autores]
Categoría Estudio primario
Registro de estudiosUMIN Clinical Trials Registry
Año 2014
Enlaces
Cargando información sobre las referencias

INTERVENTION:

Observation of changes with a cilnidipine administration. Observation of changes with a amlodipine administration.

CONDITION:

Diabetes/Hypertension/Sleep apnea syndrome

PRIMARY OUTCOME:

office blood presure; PWV; IMT; urinary albumin (diabetes only); urinary LFAB‐

P SECONDARY OUTCOME:

e‐GFR ; adiponectin; hs‐

CRP INCLUSION CRITERIA:

1) Hypertensive patients not reaching the step‐down goal, even the administration of RAS inhibitors for more than three months or no medication. 2) Diabetic nephropathy 3) Patients complicated with sleep apnea syndrome. Among the above‐mentioned; 1)+2)+3) or 1)+2) or 1)+3)
Epistemonikos ID: 8d6b381de91955dab494aeb0b77f63a6d972234a
First added on: Aug 22, 2024